# Elevara Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elevara-medicines

- Industry: Pharmaceuticals
- Headquarters: Cheshire, UK
- Website: www.elevara.com/
- Total disclosed funding: $70M
- Latest round: Series A (Oct 2, 2025)
- Investors on record: 4

## About

Based in the UK, Elevara Medicines Limited focuses on developing innovative therapies for rheumatoid arthritis and chronic inflammatory diseases, aiming to improve patient outcomes.Elevara Medicines Limited is a biotechnology company dedicated to advancing treatment options for rheumatoid arthritis. Founded in 2025, it is headquartered in London, UK. The company successfully raised USD 70.00 mn in SERIES A funding on October 2, 2025,  co-led by new investors Forbion and Sofinnova Partners, with participation from returning investors Monograph Capital and Weatherden Limited.. The funding is intended to support the advancement of its Phase 2 trial for its lead product, ELV001, targeting chronic inflammatory conditions.Elevara Medicines focuses on the development of innovative therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases, with a core product being ELV001, a once-daily small molecule designed to target the proliferation and inflammatory signaling of fibroblast-like synoviocytes (FLS). This product aims to address the unmet needs of patients who have not achieved adequate disease remission through existing immune-targeted treatments, particularly those with partial response to TNF inhibitors. The company is actively conducting the START-SYNERGY Trial, a Phase 2b clinical study evaluating ELV001 as an add-on therapy for patients experiencing inadequate responses to standard treatments like methotrexate and TNF inhibitors. Elevara's clinical studies will recruit patients across multiple geographical locations, including the United States, South Africa, Czech Republic, Poland, Bulgaria, and Serbia, thereby targeting a global market of patients suffering from RA.Elevara Medicines recently announced the successful closure of a USD 70.00 mn SERIES A financing round, co-led by Forbion and Sofinnova Partners. This indicates investor confidence in the company’s potential to generate revenue through its innovative therapeutic offerings. The revenue model will involve partnerships with healthcare providers and clinics for the distribution of ELV001 and future products within the RA treatment landscape. Transactions are likely to be structured as B2B agreements, engaging directly with hospitals and specialty pharmacies to facilitate access to their therapies, aiming to streamline treatment processes for patients and enhance compliance. The ongoing clinical trials and their results will be critical in establishing market demand and pricing strategies for ELV001 once it becomes commercially available.In October 2025, Elevara Medicines Limited raised USD 70.00 mn in SERIES A funding to advance its Phase 2 trial for ELV001 and expand into other chronic inflammatory indications. The company plans to utilize the funding to support its clinical development and potentially explore additional therapeutic areas. With its ongoing clinical studies, Elevara aims to establish a strong market presence and enhance its product offerings in the rheumatoid arthritis and chronic inflammatory disease sectors.

## Funding rounds

- Series A, Oct 2, 2025, $70M — Sofinnova Partners, Forbion, Monograph Capital, Weatherden Ltd

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series A
- Weatherden Ltd — Series A